4-Propyl-3′-Fluorobiphenyl-4′-Boronic Acid | CAS:909709-42-8

We serve 4-Propyl-3′-Fluorobiphenyl-4′-Boronic Acid CAS:909709-42-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Propyl-3'-Fluorobiphenyl-4'-Boronic Acid

Product Name: 4-Propyl-3'-Fluorobiphenyl-4'-Boronic Acid
Other Name:
4-Propyl-3'-Fluorobiphenyl-4'-Boronic Acid
[2-fluoro-4-(4-propylphenyl)phenyl]boronic acid
(3-Fluoro-4'-propyl-4-biphenylyl)boronic acid
4'-Propyl-3-fluoro-4-biphenyl boronic acid
CAS No: 909709-42-8
MF: C15H16BFO2
MW: 258.09600
Density: 1.2±0.1 g/cm3
Boiling point: 412.5±55.0 °C at 760 mmHg
Melting point: N/A
Flash point: 203.3±31.5 °C
Refractive index: 1.567
UN Number: Non-dangerous goods
Transport hazard class: Non-dangerous goods
Packing group: Non-dangerous goods
 
Specification
Appearance: White powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate, OLED intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like 4-Propyl-3′-Fluorobiphenyl-4′-Boronic Acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4′-Propyl-3-fluoro-4-biphenyl boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(3-Fluoro-4′-propyl-4-biphenylyl)boronic acid Use and application,4′-Propyl-3-fluoro-4-biphenyl boronic acid technical grade,usp/ep/jp grade.


Related News: Active pharmaceutical ingredients affect the structure and function of the human body. Inactive ingredients in a pharmaceutical may be referred to as “bulk pharmaceutical chemicals (BPCs).”cis-8,11,14-Eicosatrienoic Acid manufacturer As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.triphenylsilanol supplier As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.3-Bromo-2-fluorophenylmethanol vendor The South Korean government is banning entry to all foreign nationals who visited China’s Hubei province in the past 14 days.A 40-year-old Chinese woman also tested positive. She was already in quarantine as she is related to another patient who contracted the virus.